Denmark Downgrades 2025 GDP Growth Forecast to 1.4% Amid Novo Nordisk Weakness and Tariff Hike
PorAinvest
viernes, 29 de agosto de 2025, 4:05 am ET1 min de lectura
NVO--
The primary driver behind this adjustment is the declining performance of Novo Nordisk, which has seen its market share in the US erode due to increased competition and the rise of generic medicines. The company, known for its blockbuster weight management drugs Ozempic and Wegovy, has had to cut its sales and profit guidance twice this year [3]. This has led to a significant drop in Denmark's exports, which are now expected to grow by only 0.9% in 2025 [4].
Denmark's Economy Minister Stephanie Lose stated that while the pharmaceutical industry remains crucial to the country's economy, the rapid growth seen in recent years is unlikely to continue at the same pace [1]. Despite the downward revision, the minister highlighted that Denmark's economy remains robust, with high employment and inflation expected to be below 2% annually [3].
The Danish government has also revised its 2026 growth forecast to 2.1%, up from 1.4%, indicating a more optimistic outlook for the following year [3]. This upward revision is attributed to anticipated increases in private and public consumption.
References:
[1] https://www.bloomberg.com/news/articles/2025-08-28/denmark-slashes-economic-growth-forecast-as-novo-nordisk-slumps
[2] https://www.marketscreener.com/news/denmark-halves-economic-growth-outlook-on-novo-nordisk-weakness-tariff-hit-bloomberg-says-citing-ce7c50dcd18ff72d
[3] https://www.cnbc.com/2025/08/29/denmark-slashes-2025-growth-forecast-amid-novo-nordisk-slowdown-.html
[4] https://www.investing.com/news/stock-market-news/denmark-halves-economic-growth-forecast-on-novo-nordisk-weakness-bloomberg-says-4215611
Denmark has halved its 2025 GDP growth forecast to 1.4% from 3% due to weaker prospects for Novo Nordisk and US tariff increases. Exports are expected to grow just 0.9% in 2025, down from 4.3% in May. The pharmaceutical industry remains key to Denmark's economy but is expected to slow down.
Denmark has significantly reduced its 2025 GDP growth forecast to 1.4% from an earlier estimate of 3%, citing weaker prospects for pharmaceutical giant Novo Nordisk and the impact of US tariff increases [1]. The Danish government has revised its export growth expectation for 2025 to just 0.9%, a substantial decrease from the May forecast of 4.3% [2].The primary driver behind this adjustment is the declining performance of Novo Nordisk, which has seen its market share in the US erode due to increased competition and the rise of generic medicines. The company, known for its blockbuster weight management drugs Ozempic and Wegovy, has had to cut its sales and profit guidance twice this year [3]. This has led to a significant drop in Denmark's exports, which are now expected to grow by only 0.9% in 2025 [4].
Denmark's Economy Minister Stephanie Lose stated that while the pharmaceutical industry remains crucial to the country's economy, the rapid growth seen in recent years is unlikely to continue at the same pace [1]. Despite the downward revision, the minister highlighted that Denmark's economy remains robust, with high employment and inflation expected to be below 2% annually [3].
The Danish government has also revised its 2026 growth forecast to 2.1%, up from 1.4%, indicating a more optimistic outlook for the following year [3]. This upward revision is attributed to anticipated increases in private and public consumption.
References:
[1] https://www.bloomberg.com/news/articles/2025-08-28/denmark-slashes-economic-growth-forecast-as-novo-nordisk-slumps
[2] https://www.marketscreener.com/news/denmark-halves-economic-growth-outlook-on-novo-nordisk-weakness-tariff-hit-bloomberg-says-citing-ce7c50dcd18ff72d
[3] https://www.cnbc.com/2025/08/29/denmark-slashes-2025-growth-forecast-amid-novo-nordisk-slowdown-.html
[4] https://www.investing.com/news/stock-market-news/denmark-halves-economic-growth-forecast-on-novo-nordisk-weakness-bloomberg-says-4215611

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema



Comentarios
Aún no hay comentarios